SYM-2206

CAS No. 173952-44-8

SYM-2206( SYM2206 )

Catalog No. M12640 CAS No. 173952-44-8

An allosteric, non-competitive antagonist of the AMPA receptor with IC50 of 2.8 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 85 In Stock
5MG 77 In Stock
10MG 123 In Stock
25MG 261 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SYM-2206
  • Note
    Research use only, not for human use.
  • Brief Description
    An allosteric, non-competitive antagonist of the AMPA receptor with IC50 of 2.8 uM.
  • Description
    An allosteric, non-competitive antagonist of the AMPA receptor with IC50 of 2.8 uM; acts allosterically at the same regulatory site as GYKI 52466 and 53655 and other benzodiazepines but does not bind to the central diazepine binding site; shows selectivity for AMPA relative to kainate receptor sub-types.Epilepsy Discontinued.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    SYM2206
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    iGluR
  • Recptor
    iGluR
  • Research Area
    Neurological Disease
  • Indication
    Epilepsy

Chemical Information

  • CAS Number
    173952-44-8
  • Formula Weight
    366.4137
  • Molecular Formula
    C20H22N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(N1N=C(C2=CC=C(N)C=C2)C3=CC(OCO4)=C4C=C3C1C)NCCC
  • Chemical Name
    1,3-Dioxolo[4,5-g]phthalazine-6(5H)-carboxamide, 8-(4-aminophenyl)-5-methyl-N-propyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Pei XF, et al. Bioorg Med Chem Lett. 1999 Feb 22;9(4):539-42. 2. Li P, et al. Nature. 1999 Jan 14;397(6715):161-4. 3. Behr J, et al. Eur J Neurosci. 2002 Sep;16(5):861-7.
molnova catalog
related products
  • LY450108

    LY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.

  • Conantokin G

    GluN2B (formally NR2B) selective, competitive antagonist of the NMDA receptor. Blocks NMDA-evoked current in mouse cortical neurons (IC50 = 480 nM); also inhibits NMDA-evoked responses in oocytes expressing GluN2B (formally NR2B), but not GluN2A (formally NR2A), subunits (IC50 ~300 nM). Exhibits neuroprotective properties in vivo and in vitro.

  • Rislenemdaz

    A potent, orally bioavailable brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively.